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Abstract
Motavizumab (MEDI-524) is a monoclonal antibody with enhanced neutralizing activity against RSV.
In mice, motavizumab suppressed RSV replication which resulted in significant reduction of clinical
parameters of disease severity. We evaluated the effect of motavizumab on the local and systemic
immune response induced by RSV in the mouse model. Balb/c mice were intranasally inoculated
with 106.5 PFU RSV A2 or medium. Motavizumab was given once intraperitoneally (1.25 mg/mouse)
as prophylaxis, 24 h before virus inoculation. Bronchoalveolar lavage (BAL) and serum samples
were obtained at days 1, 5 (acute) and 28 (long-term) post inoculation and analyzed with a multiplex
assay (Beadlyte Upstate, NY) for simultaneous quantitation of 18 cytokines: IL-1α, IL-1β, IL-2, IL-
3, IL-4, IL-5, IL-6, KC (similar to human IL-8), IL-10, IL-12p40, IL-12p70, IL-13, IL-17, TNF-α, MCP-
1, RANTES, IFN-γ and GM-CSF. Overall, cytokine concentrations were lower in serum than in BAL
samples. By day 28, only KC was detected in BAL specimens at low concentrations in all groups.
Administration of motavizumab significantly reduced (p < 0.05) BAL concentrations of IL-1α, IL-
12p70 and TNF-α on day 1, and concentrations of IFN-γ on days 1 and 5 compared with RSV-
infected untreated controls. In the systemic compartment, the concentrations of IL-10, IFN-γ and
KC were significantly reduced in the motavizumab-treated mice compared with the untreated
controls. In summary, prophylactic administration of motavizumab was associated with significant
reductions on RSV replication and concentrations of cytokine and chemokines, which are likely
related to the improvement observed in clinical markers of disease severity.
Findings
Respiratory Syncytial Virus (RSV) is the main viral respira-
tory pathogen causing hospitalization in infants and
young children worldwide[1]. It infects nearly 70% of
infants in their first year of life and almost all children by
the age of two [2]. The mechanisms by which RSV causes
pulmonary disease and more specifically which factors
determine disease severity still remains to be fully charac-
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terized. It is increasingly appreciated that symptoms and
signs of RSV are caused not only by the direct viral cyto-
pathic effect but also by the host response to infection.
Nonetheless, in RSV disease both viral replication and the
exaggerated immune response to RSV infection are closely
interrelated. In fact, studies suggest that the pattern of
cytokine production elicited by RSV affects the balance
between virus replication and disease pathogenesis, that
ultimately determines the manifestations of the disease
[3].
In the present study we took an alternative approach to
explore the relative importance and role that different
cytokines and chemokines play in acute RSV disease sever-
ity.
Instead of targeting individual cytokines as potential ther-
apeutic targets, we took advantage of our experience with
motavizumab. We previously showed that the superior
neutralizing activity of this anti-RSV monoclonal anti-
body compared with palivizumab was associated with fur-
ther reductions in RSV replication which in turn resulted
in additional improvement in clinical disease severity
[4,5]. The present study was designed to assess the effect
of motavizumab on the cytokine and chemokine
responses induced by RSV both in the respiratory tract and
in the systemic compartment, which, we hypothesized,
were likely associated with the observed improvement in
disease severity.
Seven-week-old female, pathogen-free BALB/c mice
(Charles River) were intranasally inoculated with 100 µL
of 106.5 PFU RSV-A2 or sterile 10% Eagle's minimal essen-
tial medium, following institutional guidelines [5-7].
Motavizumab was administered intraperitoneally 24 h
before RSV inoculation (1.25 mg in 0.1 ml of PBS/per
mouse) [5]. Our previous studies showed that no treat-
ment or treatment with either PBS or an IgG1 isotype-
matched control antibody, MEDI-507, at the same time of
the administration of the anti-RSV antibody had no effect
on the cytokine profile or other clinical and inflammatory
parameters evaluated, therefore those controls were not
included in the study [8]. Bronchoalveolar lavage (BAL)
and serum samples from 4–6 mice per time point/group
from two independent experiments were obtained during
the acute, (days 1 and 5 post-inoculation) and chronic
(day 28) phases of the disease. Paired BAL and serum sam-
ples from non-infected controls, RSV-infected untreated,
and RSV-infected mice treated with motavizumab previ-
ously stored at -80°C, were randomly selected within the
two experiments (4 mice per time-point/group) for
cytokine analysis using the Beadlyte Mouse Multi-
Cytokine Detection System (Upstate Biotechnology, Lake
Placid NY) and the Luminex100 plate reader (Luminex
Corporation, Austin, TX) according to manufacturer's
instructions. Quantification of cytokines was performed
by regression analysis from a standard curve generated
from cytokine standards included in the kit with a lower
limit of detection of 10 pg/ml for all cytokines evaluated.
The plaque assay, which has a lower limit of detection of
1.7 log10 PFU/mL, was used to measure RSV viral loads in
BAL specimens as previously described [5-7]. Disease
severity was assessed by whole-body plethysmograph
(Buxco, Troy, NY) to evaluate airway obstruction (AO) by
measuring the enhanced pause [7-9]. According to data
distribution, Mann-Whitney rank sum test or t-test were
used for analyses. Since the concentrations of the
cytokines/chemokines evaluated were detected either at a
very low level or were below the level of detection of the
assay in the non-infected control group, and the objective
of the study was to evaluate the effect of motavizumab in
the inflammatory response induced by RSV, the unin-
fected control group was not included in the statistical
analyses.
Motavizumab prophylaxis completely prevented the
development of clinical disease objectively assessed by
measuring the AO; in fact, mice treated with the mAb
remained clinically asymptomatic throughout the experi-
ment compared with the RSV-infected untreated mice
(Figure 1). Furthermore, motavizumab administration
resulted in significant reductions of RSV loads compared
Effect of the anti-RSV mAb (motavizumab) on pulmonary  function Figure 1
Effect of the anti-RSV mAb (motavizumab) on pul-
monary function. Airway obstruction was assessed by 
whole body plethysmograph by measuring basal Penh daily 
during the first two weeks after infection and weekly up to 
day 28. Values represent median; errors bars, 25th–75th per-
centile. Each group consisted of 8 mice. Results of two sepa-
rate experiments are shown. * p < 0.001 by Kruskal-Wallis 
ANOVA on ranks for comparison between RSV-infected 
untreated, sham inoculated controls and RSV-infected 
treated with motavizumab at -24 h.
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with untreated controls on days 1 and 5 (< 1.7 PFU/ml
log10 vs 2.45 [2.22–2.53] on day 1 and 3.12 [2.73–3. 39]
on day 5; p < 0.05).
Eighteen cytokines, including interleukins (IL)-1α, -1β, -
2, -3, -4, -5, -6, KC (similar to human IL-8), IL-10, -12p40/
70, -13, -17, tumor necrosis factor-α (TNF-α), macro-
phage chemoattractant protein-1 (MCP-1), Regulated
upon Activation, Normal T-cell Expressed and Secreted
(RANTES), interferon-γ (IFN-γ) and granulocyte macro-
phage colony-stimulating factor (GM-CSF) were meas-
ured using a multiplex antibody assay. Except for IL-10,
MCP-1, IL-1β and IL-12p70 concentrations, the effect of
motavizumab on the cytokine profile was more evident in
the respiratory tract (BAL) than in serum. This could be
explained in part because fewer cytokines were detected in
serum and also because the concentrations were lower in
serum than in BAL specimens.
On day 1, BAL concentrations of IL-1α, IL-12p70, TNF-α
and IFN-γ and serum IL-10 and KC were significantly
lower in mice treated with motavizumab compared with
RSV-infected untreated mice (Table 1). The role of TNF-α
in RSV disease is not completely understood. While some
authors have suggested that TNF-α has a protective role in
RSV infection, others have related the RSV-induced lung
damage to the overproduction of TNF-α [10,11]. In our
previous studies, palivizumab administration did not
modify BAL concentrations of TNF-α nor the initial peak
of airway obstruction (AO) observed in this model [8]. In
contrast, motavizumab significantly reduced BAL concen-
trations of TNF-α, and this was unexpectedly associated
with suppression of the initial peak of AO on day 1.
Although the pathogenesis of the first peak of AO in this
model is not completely understood, this is the first time
that we observed its suppression, suggesting that early
production of TNF-α may play a major role in initiating
airway disease.
Our previous studies showed that tracheal aspirate con-
centrations of RANTES, IL-8 and IL-10 in children intu-
bated with severe RSV inversely correlated with clinical
disease severity, however these cytokines were not meas-
ured in serum [12]. Interleukin-10, an anti-inflammatory/
regulatory cytokine, has been shown not only to be an
important component of the pathogenesis of acute RSV
bronchiolitis but to also play a role in the enhanced air-
way hyperreactivity that occurs after RSV infection
[13,14]. In our study, motavizumab significantly
decreased serum concentrations of KC (chemoattractant
for neutrophils, the predominant lung inflammatory cell
during acute RSV) and IL-10, two cytokines that play a
major role in the pathogenesis of RSV bronchiolitis [13].
BAL concentrations of IL-6, RANTES and MCP-1 were also
decreased in the motavizumab group, but likely due to
small numbers there was insufficient power to achieve sta-
tistical significance (Tables 1, 2).
On day 5, the peak of viral replication and lung inflamma-
tion in this model, both serum and BAL concentrations of
INF-γ were significantly decreased in the motavizumab
group (Table 2). To date, there is still no consensus on the
role of INF-γ in RSV pathogenesis and its responses may
vary depending on disease severity [15-17]. Mice treated
with motavizumab had no virus detected by culture in the
respiratory tract, (< 1.7 PFU/mL log10) and this reduction
in virus load was associated with significantly decreased
local and systemic IFN-γ concentrations, and more impor-
tantly with no evidence of AO in these mice suggesting a
pivotal role of INF-γ in the pathogenesis of RSV disease.
Table 1: BAL/serum cytokine concentrations (pg/mL) in RSV infected mice treated with motavizumab compared with untreated RSV 
infected controls on day 1 after inoculation. Each group consisted of 4 samples randomly selected from two independent experiments.
BAL (D1) SERUM (D1)
RSV Untreated RSV Motavizumab p value RSV Untreated RSV motavizumab p value
IFN-γ 67.16 ± (24.6) 28.01 ± (13.8) 0.03 ND ND ---
MCP-1 1930.68 ± (716.6) 1088.12 ± (307.8) 0.07 381.83 (341.0–554.8) 230.65 (217.43–298.83) 0.6
RANTES 1952.10 ± (999.05) 671.66 ± (340.4) 0.051 ND ND ---
IL-10 39.29 ± (27.0) 14.47 ± (7.8) 0.1 102.23 ± (22.5) 16.78 ± (13.56) 0.001
TNF-α 2290.90 ± (1100.2) 279.03 ± (204.7) 0.01 ND ND ---
GM-CSF 101.42 (45.7–144.9) 25.14 (22.1–34.0) 0.1 ND ND ---
IL-12p70 44.14 ± (13.5) 22.59 ± (8.7) 0.03 45.85 ± (17.5) 23.75 ± (16.1) 0.16
KC 3967.43 (2039.8–5795.3) 1303.57 (946.4–1657.1) 0.1 215.86 ± (125.8) 37.63 ± (32.5) 0.03
IL-6 2580.89 ± (1413.6) 821.79 ± (290.13) 0.051 91.39 (45.43–135.31) 31.17 (18.97–35.85) 0.2
IL-1β 477.52 (231.53–831.92) 182.78 (179.4–214.3) 0.3 266.88 ± (74.4) 119.70 ± (143.5) 0.16
IL-1α 289.75 ± (114.0) 76.28 ± (29.1) 0.01 ND ND ---
IL-17 ND ND --- 20.68 (11.94–31.85) 10.67 (10.06–12.03) 0.2
Note: Data are shown as mean ± SD, or medians and 25–75% range as appropriate according to whether they were normally distributed. ND (non-
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The fact that substantial IFN-γ was detected on day 5
despite treatment with the mAb suggests that some viral
particles still escaped the effect of the enhanced neutraliz-
ing antibody. This interpretation of the results is further
supported by our previous experiments in which UV-inac-
tivated virus did not induce an INF-γ response [7].
By day 28, only KC was detected in BAL specimens at low
concentrations without significant differences between
groups.
Taking together, these results suggest that not only the
local but also the systemic cytokine immune response
influence the severity of acute RSV disease, and that RSV
clinical disease can be modified with the use of a specific
anti-RSV neutralizing antibody directed against a well
conserved epitope of the RSV F protein.
In summary, in the mouse model, prophylactic adminis-
tration of motavizumab significantly decreased RSV repli-
cation, the local and systemic cytokine responses,
especially TNFα, IL-1α, IL-12p70, KC, IL-10 and INF-γ,
and completely prevented the development of clinical
acute RSV disease. Future studies in humans treated with
anti-RSV antibodies should determine whether changes in
clinical markers of disease severity correlate with similar
changes in cytokine profiles. These studies will provide
further understanding of the pathogenesis of RSV infec-
tion and should help identifying new targets for develop-
ing immunomodulatory therapies.
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